Guselkumab for the treatment of moderate to severe plaque psoriasis
ABSTRACT Introduction: Guselkumab is a human monoclonal antibody targeting the p19 subunit of IL 23 that has been approved for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. This medication blocks the IL 23/IL 17 axis, which has been implicated in playing a key role in the pathogenesis of psoriasis. Areas covered: This review outlines the pharmacologic properties, safety, and efficacy of guselkumab for the treatment of plaque psoriasis. Expert commentary: Guselkumab is the first IL 23 specific inhibitor to be approved for the treatment of plaque psoriasis. Phase II and III clinical trial results have demonstrated excellent safety and efficacy of guselkumab. IL 23 inhibitors may offer potential benefits over existing therapies for moderate to severe plaque psoriasis in terms of safety, frequency of administration, and efficacy. Long term safety data will be critical in evaluating the role of guselkumab in the treatment of psoriasis.
Expert review of clinical pharmacology